Skip to main
LUCD
LUCD logo

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. operates within a crucial niche of the medical diagnostics sector, specifically targeting patients with gastroesophageal reflux disease (GERD) who face the risk of developing severe esophageal conditions, positioning the company for substantial market demand. Recent advancements in negotiations with Medicare suggest that favorable coverage decisions could soon enhance broader accessibility and adoption of its flagship products, EsoCheck and EsoGuard. Additionally, Lucid's first mover advantage and the superior efficacy of EsoGuard place the company in a strong position as a potential acquisition target, further bolstering its attractiveness as an investment opportunity.

Bears say

Lucid Diagnostics Inc. reported a pro forma net loss of $9.9 million, or an earnings per share (EPS) of $(0.10), which was slightly worse than company estimates and consensus expectations. Additionally, the volume of EsoGuard tests processed decreased to 2,756 in Q2, marking a decline from previous quarters, indicating potential challenges in product adoption and market penetration. The company's outlook is further complicated by various risks, including balance sheet and liquidity concerns, regulatory hurdles, and intense competition in the biotech and medtech sectors.

Lucid Diagnostics (LUCD) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.